MIMEDX to Sponsor Leading Advanced Wound Care Conferences

Rhea-AI Summary

MiMedx Group (Nasdaq: MDXG) will sponsor and present at two leading wound care conferences: SAWC Spring 2026 (April 8–12, Charlotte) and DLS 2026 (April 8–11, Washington, D.C.).

Activities include sponsored symposia, multiple poster and oral clinical presentations, and exhibit booths to showcase peptide-based and placental allograft wound-care technologies.

AI-generated analysis. Not financial advice.

News Market Reaction – MDXG

-0.76%

1 alert

-0.76% News Effect

On the day this news was published, MDXG declined 0.76%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

SAWC Spring 2026 dates: April 8–12, 2026 DLS 2026 dates: April 8–11, 2026 SAWC booth: Booth 809 +3 more

6 metrics

SAWC Spring 2026 dates April 8–12, 2026 Symposium on Advanced Wound Care in Charlotte, NC

DLS 2026 dates April 8–11, 2026 Diabetic Limb Salvage Conference in Washington, D.C.

SAWC booth Booth 809 MIMEDX exhibit location at SAWC Spring 2026

SAWC lunch symposium time 12:15–1:45 p.m. Lunch symposium on April 9, Room 208

Oral abstracts session time 10:30–11:30 a.m. SAWC oral abstracts featuring G4Derm Plus

DLS lunch symposium time 12:30–1:30 p.m. Lunch Symposium III at DLS 2026

Market Reality Check

Price: $3.56 Vol: Volume 1,456,848 vs 20-da...

normal vol

$3.56 Last Close

Volume Volume 1,456,848 vs 20-day average 1,109,199 (relative volume 1.31x). normal

Technical Price 3.95, trading below 200-day MA at 6.32, well under the 52-week high 7.99 and near the 52-week low 3.77.

Peers on Argus

Sector peers show mixed moves: MRVI +1.06%, ATNF +2.92%, NTLA +2.47%, XERS +2.55...

Sector peers show mixed moves: MRVI +1.06%, ATNF +2.92%, NTLA +2.47%, XERS +2.55%, while MAZE -4.63%. No momentum scanner flags and no same-day peer news, indicating this conference-focused headline is more company-specific than part of a broad sector move.

Historical Context

5 past events · Latest: Mar 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 23	Product launch	Positive	+2.9%	Launch of CHORIOFIX placental allograft for non-healing diabetic foot ulcers.
Mar 05	Product launch	Positive	-1.4%	Launch of AMNIOFIX Thyroid Shields for endocrine surgery nerve protection.
Feb 25	Earnings results	Positive	-1.3%	Record Q4 and 2025 net sales, profitability, and new share repurchase authorization.
Feb 17	Earnings call notice	Neutral	+0.8%	Scheduling of Q4 and full-year 2025 results webcast and conference call.
Feb 04	Distribution deal	Positive	+2.8%	Exclusive distribution agreement for three 510(k)-cleared surgical and wound products.

Pattern Detected

Product and partnership news often saw positive moves, while strong financial results and some launches produced mild negative reactions, indicating mixed alignment between news tone and price.

Recent Company History

Over recent months, MIMEDX reported several developments, including the launch of CHORIOFIX on Mar 23, 2026, new AMNIOFIX Thyroid Shields on Mar 5, 2026, and an exclusive distribution agreement for Hydrelix, NovaForm, and G4Derm Plus on Feb 4, 2026. Record Q4 2025 and full-year results were announced on Feb 25, 2026, with strong growth figures but a modest negative price reaction. Today’s conference participation news fits the pattern of ongoing commercial and clinical visibility building on this product and financial momentum.

Market Pulse Summary

This announcement highlights MIMEDX’s visibility at major wound care meetings, with multiple symposi...

Analysis

This announcement highlights MIMEDX’s visibility at major wound care meetings, with multiple symposiums and posters emphasizing peptide-based and placental tissue technologies. It follows earlier launches such as CHORIOFIX and new distribution agreements, pointing to continued commercial and clinical outreach. With the stock trading below its 200-day MA of 6.32 and close to its 52-week low of 3.77, investors may watch for how this scientific presence converts into adoption, sales trends, and future clinical data.

Key Terms

peptide-based technology, peptide-based biomimetic matrix, dehydrated human umbilical cord, lyophilized human amnion chorion membrane, +4 more

8 terms

peptide-based technology medical

"Innovative Peptide-Based Technology Provides Antibacterial Protection, Facilitating..."

Peptide-based technology uses short chains of amino acids—like tiny custom-made keys—to create drugs, diagnostics, or delivery systems that fit specific biological targets. Investors care because these assets can offer precise effects with potentially fewer side effects, clear intellectual property paths, and scalable manufacturing, which can lead to high upside if clinical and regulatory hurdles are cleared, but also carry development and approval risk.

peptide-based biomimetic matrix medical

"Peptide-Based Biomimetic Matrix Eliminates Multidrug-Resistant Pseudomonas..."

A peptide-based biomimetic matrix is a lab-made scaffold built from short protein pieces that mimic the natural structure surrounding cells, helping tissues grow, heal, or accept implants. Think of it as a biodegradable mesh that guides and supports cell repair much like a trellis guides a climbing plant. Investors watch it because it can be a scalable technology platform for regenerative medicines, wound care, or targeted drug delivery and may drive product differentiation, pricing power, and regulatory milestones.

dehydrated human umbilical cord medical

"Dehydrated Human Umbilical Cord Modulates the Effects of TGFβ-Mediated..."

A dehydrated human umbilical cord is human birth-tissue that has been cleaned, dried and preserved so it can be stored and used later as a biological graft to help heal wounds and support surgical repairs. Think of it like a natural, ready-made bandage that delivers structural proteins and signaling molecules to injured tissue; investors track it because its safety, clinical effectiveness, regulatory clearance, and supply chain affect adoption, market size, and recurring revenue potential.

lyophilized human amnion chorion membrane medical

"Lyophilized Human Amnion Chorion Membrane Allografts Modify Inflammatory..."

A lyophilized human amnion chorion membrane is a freeze‑dried graft made from the innermost layers of the human placenta that has been processed to preserve natural proteins and structural tissue. Think of it as a biological bandage that can be rehydrated and placed on wounds or surgical sites to support healing and reduce scarring; clinical effectiveness, regulatory clearance, manufacturing capacity and reimbursement determine its commercial value to investors.

placental allografts medical

"Post-Acute Care of Stalled Pressure Injuries with Placental Allografts"

Human placental allografts are biological products made from donated placenta tissue that has been processed for use in medical treatments, typically to promote wound healing and tissue repair. Think of them as natural, sterile bandages or scaffolds that help the body rebuild damaged tissue; investors watch them because clinical results, regulatory approvals, manufacturing scale, and reimbursement decisions directly affect the commercial potential and risk profile of companies developing and selling these therapies.

biomimetic matrix medical

"Using a Biomimetic Matrix in Treatment-Resistant Wounds with Autoimmune..."

A biomimetic matrix is a synthetic or engineered material designed to imitate the body’s natural tissue scaffolding so cells can attach, grow, and repair damaged tissue. Think of it like a temporary trellis that guides and supports new growth in a garden. For investors, it matters because these materials underpin regenerative medicines, advanced wound care, and implantable devices—areas that can drive product value, clinical success rates, regulatory scrutiny, and long-term revenue potential.

multidrug-resistant pseudomonas medical

"Peptide-Based Biomimetic Matrix Eliminates Multidrug-Resistant Pseudomonas..."

Multidrug-resistant Pseudomonas is a strain of the common bacterium Pseudomonas aeruginosa that has evolved to survive treatment with several widely used antibiotics. Like a lock that no longer responds to many keys, it makes infections harder and more expensive to treat, increases hospital stays and complication risks, and therefore matters to investors because it can drive demand for new drugs, influence healthcare spending, affect regulatory scrutiny, and create liability or market opportunities for medical companies.

mohs micrographic surgery medical

"Following Mohs Micrographic Surgery: A Case Report"

Mohs micrographic surgery is a precise procedure to remove certain skin cancers by taking off thin layers of tissue and examining each layer under a microscope until no cancer cells remain, preserving as much healthy skin as possible. Investors pay attention because the technique shapes demand for dermatology clinics, surgical tools, lab services and insurance payments; like using a magnifying glass to pick out only the bad parts, it can lower recurrence and follow-up costs, affecting provider revenue and healthcare spending.

AI-generated analysis. Not financial advice.

Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes

Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio

MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care (“SAWC”) Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (“DLS”) Conference.

Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in managing complex wounds.

“Clinicians are facing increasingly complex patients and rising expectations for outcomes, making access to both strong clinical evidence and a broad set of treatment options more important than ever,” said John Harper, Ph.D., MIMEDX Chief Scientific Officer and SVP, R&D and Medical Affairs. “Our presence at SAWC and DLS reflects our continued commitment to advancing the science of wound care and supporting clinicians with solutions grounded in evidence, education, and real-world application.”

SAWC Spring 2026
April 8–12 | Charlotte, NC | Booth 809

MIMEDX will feature its portfolio of advanced wound care technologies and present new scientific data through a sponsored symposium and multiple accepted poster presentations.

Lunch Symposium:
Thursday, April 9 | 12:15–1:45 p.m. | Room 208
Translating Innovation into Real-World Wound Care
Speakers: Dylan Alston, MD; Trent Brookshier, DPM; Thomas Serena, MD, FACS, FACHM; Peter Moyer, DPM

Oral Abstracts (G4Derm^® Plus by Gel4Med):
Friday, April 10 | 10:30–11:30 a.m. | Session K2
Innovative Peptide-Based Technology Provides Antibacterial Protection, Facilitating Rapid and Sustained Closure of Surgical Incisions

Friday, April 10 | 10:30–11:30 a.m. | Session K3
Peptide-Based Biomimetic Matrix Eliminates Multidrug-Resistant Pseudomonas in Complex Wounds

Accepted Clinical & Scientific Poster Presentations:

1. Dehydrated Human Umbilical Cord Modulates the Effects of TGFβ-Mediated Fibrosis in Support of Wound Management
   
2. Lyophilized Human Amnion Chorion Membrane Allografts Modify Inflammatory Monocyte-derived Macrophage’s Phenotype in vitro
3. Refractory Neuropathic Foot Wounds in Medically Complex Patients: Achieving Durable Closure and Function
4. Bovine-Derived Collagen Matrix as an Adjunct for Post-Amputation Diabetic Foot Wound Dehiscence: A Two-Case Review
5. Management of a High-Tension Scalp Vertex Defect Using Lyophilized Human Amnion Chorion Membrane Following Mohs Micrographic Surgery: A Case Report
6. Post-Acute Care of Stalled Pressure Injuries with Placental Allografts
7. The Novel Use of Dual Layer Chorion Membrane in a Diabetic Polymorbid Patient: A Case Report
   

G4Derm^® Plus by Gel4Med

1. Decreasing Bacterial Burden in Infected Wounds using a 3D Biomimetic Matrix
2. Using a Biomimetic Matrix in Treatment-Resistant Wounds with Autoimmune Etiologies
3. Peptide Biomimetic Matrix Rescues High-Risk Diabetic Foot Ulcers from Amputation
4. Safety and Efficacy of a Peptide Biomimetic Matrix in Refractory Lower Extremity Wounds
5. Peptide Biomimetic Matrix shows Rapid Regranulation of Complex, Deep Wounds requiring Surgical Intervention
6. Peptide Biomimetic Matrix Revitalizes Chronic Wounds via Tissue Regrowth and Revascularization: Monitoring Progress with Multispectral NIRS Imaging

DLS 2026
April 8–11 | Washington, D.C.

As a Platinum Sponsor of the Diabetic Limb Salvage Conference, MIMEDX will engage with multidisciplinary care teams focused on improving outcomes for patients at risk of amputation. The conference emphasizes collaborative approaches to limb preservation, equipping healthcare professionals with practical strategies and clinical insights.

Lunch Symposium III:
Thursday, April 9 | 12:30–1:30 p.m.
Keys to a Limb Preservation Program & Optimized Wound Bed – Foundations for Better Healing
Speakers: Matthew J. Murphy, MD, PhD, FRCSC; Karen Bauer, DNP, CNP-FNP, CWS, FAAWC, MAPWCA

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com

FAQ

What will MiMedx (MDXG) present at SAWC Spring 2026 on April 9–10?

MiMedx will present sponsored symposia, oral abstracts, and multiple posters at SAWC Spring 2026. According to the company, presentations (April 9–10) include peptide-based biomimetic matrix data and clinical poster studies on placental and collagen matrices.

How is MiMedx (MDXG) participating in the Diabetic Limb Salvage (DLS) Conference April 8–11?

MiMedx is a Platinum sponsor and will host a lunch symposium focused on limb preservation. According to the company, the session (April 9) covers keys to limb preservation programs and optimized wound-bed strategies for clinicians.

Which MiMedx technologies will be highlighted at the conferences (MDXG)?

The company will highlight peptide-based biomimetic matrices, placental allografts, and bovine collagen adjuncts. According to the company, these technologies are featured across oral abstracts, posters, and symposia demonstrating clinical and preclinical evidence.

When and where is MiMedx’s SAWC lunch symposium during SAWC Spring 2026?

The SAWC lunch symposium is scheduled for April 9, 12:15–1:45 p.m., in Room 208 at SAWC Spring 2026. According to the company, the symposium title is "Translating Innovation into Real-World Wound Care."

What clinical topics will MiMedx posters cover at SAWC Spring 2026?

MiMedx posters cover fibrosis modulation, inflammatory macrophage phenotypes, diabetic foot wound management, and novel uses of chorion membranes. According to the company, multiple case reports and preclinical studies will be presented to clinicians and researchers.

How can clinicians engage with MiMedx (MDXG) at both conferences April 8–12 and April 8–11?

Clinicians can attend symposia, oral sessions, poster sessions, and visit the exhibit (Booth 809 at SAWC). According to the company, these venues allow direct discussion of clinical evidence and real-world applications of their wound-care products.